Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Leonardi

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Managed Care (Langhorne, Pa.)|July 31, 2004
Treating psoriasis as a T-cell mediated diseaseCraig Leonardi
Seminars in Cutaneous Medicine and Surgery|May 1, 2010
Psoriasis and Biologics. IntroductionCraig Leonardi
The Journal of Dermatological Treatment|October 17, 2008
Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasisSerena Mraz, Craig Leonardi, Luz E Colón, et al.
Journal of the American Academy of Dermatology|June 24, 2008
Rethinking eligibility creepMaryanne Kazanis, Craig Leonardi, Ken Gordon, et al.
Current Medical Research and Opinion|February 11, 2005
The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the USWilliam H Crown, Brian W Bresnahan, Lucinda S Orsini, et al.
Journal of Drugs in Dermatology : JDD|April 7, 2023
Brodalumab: 4-Year US Pharmacovigilance ReportMark Lebwohl, John Koo, Craig Leonardi, et al.
Dermatology and Therapy|November 18, 2019
Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe PsoriasisElsie Grace, Orin Goldblum, Lisa Renda, et al.
The Journal of Dermatological Treatment|July 8, 2021
Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practiceCraig Leonardi, Rei Tao, Solmaz Setayeshgar, et al.
Dermatologic Therapy|August 21, 2021
Three-year U.S. pharmacovigilance report of brodalumabMark Lebwohl, Craig Leonardi, April Armstrong, et al.
Journal of the American Academy of Dermatology|January 17, 2012
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to knowBruce E Strober, Katherine Armour, Ricardo Romiti, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Managed Care (Langhorne, Pa.)|July 31, 2004
Treating psoriasis as a T-cell mediated diseaseCraig Leonardi
Seminars in Cutaneous Medicine and Surgery|May 1, 2010
Psoriasis and Biologics. IntroductionCraig Leonardi
The Journal of Dermatological Treatment|October 17, 2008
Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasisSerena Mraz, Craig Leonardi, Luz E Colón, et al.
Journal of the American Academy of Dermatology|June 24, 2008
Rethinking eligibility creepMaryanne Kazanis, Craig Leonardi, Ken Gordon, et al.
Current Medical Research and Opinion|February 11, 2005
The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the USWilliam H Crown, Brian W Bresnahan, Lucinda S Orsini, et al.
Journal of Drugs in Dermatology : JDD|April 7, 2023
Brodalumab: 4-Year US Pharmacovigilance ReportMark Lebwohl, John Koo, Craig Leonardi, et al.
Dermatology and Therapy|November 18, 2019
Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe PsoriasisElsie Grace, Orin Goldblum, Lisa Renda, et al.
The Journal of Dermatological Treatment|July 8, 2021
Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practiceCraig Leonardi, Rei Tao, Solmaz Setayeshgar, et al.
Dermatologic Therapy|August 21, 2021
Three-year U.S. pharmacovigilance report of brodalumabMark Lebwohl, Craig Leonardi, April Armstrong, et al.
Journal of the American Academy of Dermatology|January 17, 2012
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to knowBruce E Strober, Katherine Armour, Ricardo Romiti, et al.
Pageof 5